GA-ADVA
5.10.2021 09:02:07 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has responded to calls from the US Department of Homeland Security (DHS) and National Institute of Standards and Technology (NIST) to protect critical infrastructure from the growing danger of GNSS vulnerabilities and cyber threats to positioning, navigation and timing (PNT) services with the launch of its aPNT+™ platform . This scalable solution meets all the latest guidelines for resilient PNT and is the industry’s most complete offering. It provides end-to-end control and timing network visibility for the most robust protection available against the catastrophic risks that PNT disruption poses to national security and essential assets such as power grids.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005061/en/
“Cyber threats are at an all-time high. At the same time, the infrastructure that our economies and lives depend on has never been more reliant on weak and highly vulnerable satellite signals. That’s why the US DHS and NIST are driving for PNT services to be more resilient and for network operators to implement strategies to counteract the vulnerabilities of GPS and other GNSS systems, including in-network PTP timing feeds. Our trusted aPNT+™ platform is the definitive response. Being open and scalable, it offers an end-to-end range of cost-effective solutions and the industry’s most comprehensive features for augmented resilience, robustness and cybersecurity,” said Gil Biran, general manager, Oscilloquartz, ADVA. “For industries and governments, timing is now a critical service in need of urgent protection. Our aPNT+™ platform will be the cornerstone of the most effective defense in depth strategies.”
Governments worldwide have issued guidelines to protect businesses and society from disruption to PNT services, including US Executive Order 13905, which was followed by the DHS Resilient PNT Conformance Framework and NIST Cybersecurity Framework for PNT Profile. The guidelines urge operators to swiftly implement technologies and measures to safeguard vital infrastructure. Based on these, ADVA has integrated an intelligent and scalable aPNT platform into its product portfolio. Even without GPS or GNSS timing, the solution provides an intelligent, end-to-end self-recovery system designed around a threefold framework. Integrating sophisticated multi-layer detection, multi-source backup and multi-level fault-tolerant mitigation, it delivers the highest levels of resilience, robustness and cybersecurity. This is a new standard for assured PNT services, integrating not only the DHS framework’s four levels of PNT resilience but also providing enhanced level four resilience, the highest level for trusted PNT services assurance.
“Our aPNT+™ platform will be invaluable for any critical infrastructure with a crucial dependence on PNT services. With our wide-ranging product portfolio, it offers all the building blocks to create an end-to-end solution, including advanced cesium clocks, our extensive family of PTP grandmasters from core to miniature, and our innovative sync assurance application,” said Nino De Falcis, senior director, business development, Oscilloquartz, ADVA. “From transportation to national defense, from energy to finance, today’s industries need to take action against the enormous risk to lives and livelihoods that reliance on PNT represents. Now there’s a new trusted way to prevent, respond and recover PNT services against disruption with our comprehensive aPNT+™ solution.”
Further details on ADVA’s aPNT+™ platform can be found in this guide: https://adva.li/apnt-sync-guide .
Supporting slides can be viewed here: https://adva.li/apnt-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005061/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
